rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Waters Corporation

WAT · NYSE

Health CareLife-science toolsLeading

WAT stood above a rising 150-day average in 30 of the last 52 weekly readings, including each of the last 11 weeks. It is 20.8% above that average now. Life Science Tools & Research Services: 48% of its 79 stocks in an uptrend (−5 points in four weeks); Health Care: 27% (−6 points in four weeks).

Statistics

Last close, 23 Oct 2026
453.67 −0.42%
52-week range
—
Volume
0.91M
Average volume (50 days)
—
Relative volume
—
Rotation
Leading
Weeks in an uptrend
11 in a row
Industry in uptrend
48% -5 in 4 wk
Insider buys, 12 months
$902K
Insider sales, 12 months
$2.9M
Officials’ trades on record
40

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 30 of 52 weeks.

24 Apr – 23 Oct
25%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Price and volume

$404.26$432.01$459.7611 Sep23 Sep5 Oct14 Oct23 Oct
close

Daily bars to 23 Oct 2026: 30 sessions (1Y reaches back before the first session held here, 11 Sep 2026, so this is all of them). 1D is the last two sessions and 1W the last week of the same daily bars; nothing here is intraday.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$2.7M$0$766KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars. Not yet read: institutions.

Congress and officials

40 disclosed lines: House 28, Senate 4, executive 8; 14 people.

WhoDidAmountTraded
Kevin Hern House: U.S. House ClerkOK01soldjoint$1k–$15k13 Aug 2026filed 1 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k12 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k15 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$1k–$15k23 Mar 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k18 Mar 2026filed 14 May 2026
Gilbert Ray Cisneros, Jr. House: U.S. House ClerkCA31bought$1k–$15k18 Mar 2026filed 7 Apr 2026
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07sold$1k–$15k10 Mar 2026filed 13 Apr 2026
Thomas H. Kean, Jr. House: U.S. House ClerkNJ07sold$1k–$15k13 Feb 2026filed 18 Mar 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k11 Feb 2026filed 14 May 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$100k–$250k10 Feb 2026filed 14 May 2026
Debbie Dingell House: U.S. House ClerkMI06exchanged$1k–$15k10 Feb 2026filed 23 Feb 2026
Kevin Hern House: U.S. House ClerkOK01exchangedjoint$1k–$15k9 Feb 2026filed 6 Mar 2026

Insiders

Buy orders, 12 months2
Sale orders, 12 months1
Buyers · sellers2 · 1
WhoDidSharesTraded
Christopher A. KueblerDirectorsold3,626at $397.946 Aug 2026filed 7 Aug 2026
Wei JiangDirectorbought500at $289.4616 Mar 2026filed 18 Mar 2026
Richard H. FearonDirectorbought1,000at $306.346 Mar 2026filed 10 Mar 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Still reading this part; it fills in a moment.

Everyone who traded it

Heather Knight Company insiderDirector · last 30 Sep 20260 · 0
Wei Jiang Company insiderDirector · last 30 Sep 20261 · 0
Kevin Hern HouseOK01 · last 13 Aug 20260 · 1
Christopher A. Kuebler Company insiderDirector · last 6 Aug 20260 · 11
Robert L. Carpio III Company insiderSVP Waters Analytical Sciences · last 24 Jun 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 12 Jun 20265 · 3
Amol Chaubal Company insiderSVP & Chief Financial Officer · last 12 May 20260 · 0
Jianqing Bennett Company insiderSVP Waters Adv. Diagnostics · last 6 Apr 20260 · 0
Gilbert Ray Cisneros, Jr. HouseCA31 · last 18 Mar 20265 · 0
Thomas H. Kean, Jr. HouseNJ07 · last 10 Mar 20260 · 2
Richard H. Fearon Company insiderDirector · last 6 Mar 20262 · 0
Udit Batra Company insiderPresident and CEO · last 2 Mar 20260 · 0

Same industry

OABI OmniAbLeading+61%
TXG 10x GenomicsLeading+57%
AVTR AvantorLeading+51%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+40%
SDGR SchrodingerLeading+37%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202561.1%
Operating profit marginFY 2025 · to 31 Dec 202586.1%
Free cash flow marginFY 2025 · to 31 Dec 202557.9%
Return on capital employedFY 2025 · to 31 Dec 202520.9%
Cash conversionFY 2025 · to 31 Dec 2025102%
Debt to equityFY 2025 · to 31 Dec 20250.55×
Interest coverFY 2025 · to 31 Dec 202556.18×
Research spendFY 2025 · to 31 Dec 20255.0%
Revenue growthFY 2025 · to 31 Dec 202516.6%
Earnings per share growthFY 2025 · to 31 Dec 2025330%
Share count trendFY 2025 · to 19 Feb 202664.7%
Cash and equivalentsFY 2025 · to 31 Dec 2025$587.8M

Analyst forecasts

No analyst forecasts yet.